Capstan Therapeutics showcases preclinical findings on its primary in vivo CAR-T candidate, CPTX2309, during the ACR Convergence 2024 event.

Polatuzumab Vedotin-Piiq, also known as Polivy, is an antibody-drug conjugate (ADC) developed by Genentech, a member of the Roche Group.

Neurogene has provided an update regarding its ongoing Phase 1/2 open-label clinical study assessing the NGN-401 gene therapy.

Nusinersen, developed by Biogen in collaboration with Ionis Pharmaceuticals, is an antisense oligonucleotide that targets the survival motor neuron 2 (SMN2) gene.

Adicet Bio reports the dosing of the initial lupus nephritis patient in its Phase 1 trial of ADI-001 for autoimmune conditions.

Olpasiran, a promising therapeutic agent, is a small interfering RNA (siRNA) developed by Arrowhead Pharmaceuticals.

Arrowhead Pharmaceuticals has filed a New Drug Application with the U.S. FDA for plozasiran to treat Familial Chylomicronemia Syndrome.

Rituximab is a chimeric monoclonal antibody that targets the CD20 antigen found on the surface of B cells.

Seismic Therapeutics showcases new preclinical findings for S-4321, a next-gen bifunctional agonist antibody that targets PD-1 and FcγRIIb.

Mirvetuximab soravtansine is an antibody-drug conjugate (ADC) developed by ImmunoGen, Inc., targeting folate receptor alpha (FRα).

The trial tests TGN-S11 alone and in combination with Keytruda® (pembrolizumab) for stage 4 cancer patients associated with Human Papillomavirus.

Sparsentan is a small molecule drug that targets AT1R x ETA and has been approved for use in the treatment of a variety of therapeutic areas.